amezalpat
amezalpat: developed by 1 company · 2 clinical trials tracked.
amezalpat evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could amezalpat → TPST affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Tempest Therapeutics, Inc. (TPST) first-line unresectable or metastatic hepatocellular carcino… | Phase 3 |
Clinical Trials (2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy
Primary endpoint: Overall Survival (OS)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Primary endpoint: Objective Response Rate (ORR)
Frequently asked questions
Who is developing amezalpat?
amezalpat is being developed by Tempest Therapeutics, Inc..
How many clinical trials involve amezalpat?
BioSniper tracks 2 clinical trials involving amezalpat.